SCHEMBL22774658

SCHEMBL22774658

C#CCCOCCOCCN

nearest known ligand 0.39

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
ACHE P22303 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20370850 1.00 CA2 (0.39) CA2CA9ACHE
Hydrochloric Acid SCHEMBL28720024 0.97 CA2 (0.38) CA2CA9ACHE
SCHEMBL24670111 0.97
SCHEMBL18537903 0.86 CA2 (0.42) CA2CA9ACHE
SCHEMBL17404787 0.86 CA2 (0.42) CA2CA9ACHE
SCHEMBL7132326 0.83
SCHEMBL21070374 0.82
SCHEMBL21070519 0.80 CA2 (0.37) CA2CA9
SCHEMBL17761118 0.80 CA2 (0.33) CA2CA9
SCHEMBL1491293 0.79 TSHR (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282742-A1 BENZOFURAN DERIVATIVES FOR TARGETING AUTOPHAGY Automera PTE. LTD (SG) 2025-09-11 US disclosed
EP-3983417-A1 CGRP ANTAGONIST COMPOUNDS Heptares Therapeutics Limited (GB) 2022-04-20 EP disclosed
WO-2020249970-A1 CGRP ANTAGONIST COMPOUNDS HEPTARES THERAPEUTICS LIMITED (GB) 2020-12-17 WO disclosed
WO-2020249970-A1 CGRP ANTAGONIST COMPOUNDS HEPTARES THERAPEUTICS LIMITED (GB) 2020-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282742-A1 BENZOFURAN DERIVATIVES FOR TARGETING AUTOPHAGY SQSTM1, BECN1, TFEB CA2 3307/4885CA9 4511/4885ACHE 4459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.